Effect of Crossmatching on Outcome in Organ Transplantation

References

• UNOS Scientific Registry. Cadaveric donors and cadaveric-donor transplants. UNOS Update 1994; 10: 37
   Google Scholar
• UNOS Scientific Registry. Number of patient registrations on the national transplant waiting list by month. UNOS Update 1994; 10: 37–9
   Google Scholar
• Todo S., Tzakis A., Abu-Elmagd K., et al. Current status of intestinal transplantation. Adv Surg 1994; 27: 295–316
   PubMedGoogle Scholar
• UNOS Scientific Registry. Analysis of registrations and reported deaths on UNOS OPTN waiting list. UNOS Update 1994; 10: 33
   Google Scholar
• Steime V., Siegrist C-A, Mottet A., et al. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 1994; 265: 106–9
   PubMed Web of Science ®Google Scholar
• Bjorkman P. J., Saper M. A., Samroui B., et al. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 1987; 329: 512–8
   PubMed Web of Science ®Google Scholar
• Brown J. H., Jardetzky T. S., Gorga J. C., et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993; 364: 33–9
   PubMed Web of Science ®Google Scholar
• Bodmer J. G., Marsh S. G., Albert E. D., et al. Nomenclature for factors of the HLA system, 1991. Immunobiology 1993; 187: 51–69
   PubMed Web of Science ®Google Scholar
• Kaufman J., Skjoedt K., Salomonsen J. The MHC molecules of nonmammalian vertebrates. Immunol Rev 1990; 113: 83–117
   PubMed Web of Science ®Google Scholar
• Brodsky F. M., Guagliardi L. E. The cell biology of antigen processing and presentation. Annu Rev Immunol 1991; 9: 707–14
   PubMed Web of Science ®Google Scholar
• Amigorena S., Drake J. R., Webster P., et al. Transient accumulation of new class II MHC molecules in a novel endocytic compartment in B lymphocytes. Nature 1994; 369: 113–20
   PubMed Web of Science ®Google Scholar
• Tulp A., Verwoerd D., Dobberstein B., et al. Isolation and characterization of the intracellular MHC class II compartment. Nature 1994; 369: 120–6
   PubMed Web of Science ®Google Scholar
• West M. A., Lucocq J. M., Watts C. Antigen processing and class II MHC peptide-loading compartments in human B-lymphoblastoid cells. Nature 1994; 369: 147–51
   PubMed Web of Science ®Google Scholar
• Qiu Y., Xu X., Wandinger-Ness A., et al. Separation of subcellular compartments containing distinct functional forms of MHC class II. J Cell Biol 1994; 125: 595–605
   PubMed Web of Science ®Google Scholar
• Morris P., Shaman J., Attaya M., et al. An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature 1994; 368: 551–4
   PubMed Web of Science ®Google Scholar
• Fling S. P., Arp B., Pious D. HLA-DMA and -DMB genes are both required for MHC class II/ peptide complex formation in antigen-presenting cells. Nature 1994; 368: 554–8
   PubMed Web of Science ®Google Scholar
• Watschinger B., Gallon L., Carpenter C. B., et al. Mechanisms of allo-recognition. Recognition by in vivo-primed T cells of specific major histocompatibility complex polymorphisms presented as peptides by responder antigen-presenting cells. Transplantation 1994; 57: 572–6
   PubMed Web of Science ®Google Scholar
• Dalchau R., Fangmann J., Fabre J. W. Allorecognition of isolated, denatured chains of class I and class II major histocompatibility complex molecules. Evidence for an important role for indirect allorecognition in transplantation. Eur J Immunol. 1992; 22: 669–77
   PubMed Web of Science ®Google Scholar
• Heath W. R., Kane K. P., Mescher M. F., et al. Alloreactive T cells discriminate among a diverse set of endogenous peptides. Proc Natl Acad Sci USA 1991; 88: 5101–5
   PubMed Web of Science ®Google Scholar
• Linsley P. S., Brady W., Grosmaire L., et al. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med. 1991; 173: 721–30
   PubMed Web of Science ®Google Scholar
• Koulova L., Clark E. A., Shu G., et al. The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells. J Exp Med. 1991; 173: 759–62
   PubMed Web of Science ®Google Scholar
• Gimmi C. D., Freeman G. J., Gribben J. G., et al. B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc Natl Acad Sci USA 1991; 88: 6575–9
   PubMed Web of Science ®Google Scholar
• Gimmi C. D., Freeman G. J., Gribben J. G., et al. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 1993; 90: 6586–90
   PubMed Web of Science ®Google Scholar
• Linsley P. S., Brady W., Urnes M., et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991; 174: 561–9
   PubMed Web of Science ®Google Scholar
• Boussiotis V. A., Freeman G. J., Gribben J. G., et al. Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation. Proc Natl Acad Sci USA 1993; 90: 11059–63
   PubMed Web of Science ®Google Scholar
• Chen C, Gault A., Shen L, et al. Molecular cloning and expression of early T cell costimulatory molecule-1 and its characterization as B7–2 molecule. J Immunol. 1994; 152: 4929–36
   PubMed Web of Science ®Google Scholar
• Freeman G. J., Gribben J. G., Boussiotis V. A., et al. Cloning of B7–2: a CTLA-4 counterreceptor that costimulates human T cell proliferation. Nature 1993; 366: 909–11
   Google Scholar
• Lenschow D. J., Su G. H., Zuckerman L. A., et al. Expression and functional significance of an additional ligand for CTLA-4. Proc Natl Acad Sci USA 1993; 90: 11054–8
   PubMed Web of Science ®Google Scholar
• Hintzen R. Q., de Jong R., Lens SMA, et al. CD27: marker and mediator of T-cell activation%. Immunol Today 1994; 15: 307–11
   PubMedGoogle Scholar
• Campanero M. R., del Pozo M. A., Arroyo A. G., et al. ICAM-3 interacts with LFA-1 and regulates the LFA-MCAM-1 cell adhesion pathway. J Cell Biol. 1993; 123: 1007–16
   PubMed Web of Science ®Google Scholar
• Hemandez-Caselles T., Rubio G., Campanero M. R., et al. ICAM-3, the third LFA-1 counterreceptor, is a co-stimulatory molecule for both resting and activated T lymphocytes. Eur J Immunol 1993; 23: 2799–806
   PubMed Web of Science ®Google Scholar
• Brown M. H., Cantrell D. A., Brattsand G., et al. The CD2 antigen associates with the T-cell antigen receptor CD3 antigen complex on the surface of human T lymphocytes. Nature 1989; 339: 551–3
   PubMed Web of Science ®Google Scholar
• Beyers A. D., Spruyt L. L., Williams A. F. Molecular associations between the T-lymphocyte antigen receptor complex and the surface antigens CD2, CD4, or CD8 and CD5. Proc Natl Acad Sci USA 1992; 89: 2945–9
   PubMed Web of Science ®Google Scholar
• Cayabyab M., Phillips J. H., Lanier L. L. CD40 preferentially costimulates activation of CD4+ T lymphocytes. J Immunol. 1994; 152: 1523–31
   PubMed Web of Science ®Google Scholar
• Pichler W. J., Wyss-Coray T. T cells as antigen-presenting cells. Immunol Today. 1994; 15: 312–5
   PubMedGoogle Scholar
• Rudd C. E., Janssen O., Cai Y., et al. Two-step TCRzeta/CD3-CD4 and CD28 signalling in T cells: SH2/SH3 domains, protein-tyrosine and lipid kinases. Immunol Today. 1994; 15: 225–34
   PubMedGoogle Scholar
• June C. H., Bluestone J. A., Nadler L. M., et al. The B7 and CD28 receptor families. Immunol Today 1994; 15: 321–31
   PubMedGoogle Scholar
• Mampaso F, Sanchez-Madrid F., Marcen R, et al. Expression of adhesion molecules in allograft renal dysfunction. A distinct diagnostic pattern in rejection and cyclosporine nephrotoxicity. Transplantation 1993; 56: 687–91
   PubMed Web of Science ®Google Scholar
• Suranyi M. G., Bishop G. A., Clayberger C., et al. Lymphocyte adhesion molecules in T cell-mediated lysis of human kidney cells. Kidney Int 1991; 39: 312–9
   PubMed Web of Science ®Google Scholar
• Shimizu Y., Shaw S. Lymphocyte interactions with extracellular matrix. FASEB J 1991; 5: 2292–9
   PubMed Web of Science ®Google Scholar
• Pober J. S., Cotran R. S. The role of endothelial cells in inflammation. Transplantation 1990; 50: 537–44
   PubMed Web of Science ®Google Scholar
• Steinhoff G., Behrend M., Wonigeit K. Expression of adhesion molecules on lymphocytes/ monocytes and hepatocytes in human liver grafts. Hum Immunol 1990; 28: 123–7
   PubMed Web of Science ®Google Scholar
• Maguire J. E., Gresser I., Williams A. H., et al. Modulation of expression of MHC antigens in the kidneys of mice by murine interferon-alpha/beta. Transplantation 1990; 49: 130–4
   PubMed Web of Science ®Google Scholar
• Halloran P. F., Urmson J., Van der Meide P. H., et al. Regulation of MHC expression in vivo. II. IFN-alpha/beta inducers and recombinant IFN-alpha modulate MHC antigen expression in mouse tissues. J Immunol. 1989; 142: 4241–7
   PubMed Web of Science ®Google Scholar
• Skoskiewicz M. J., Colvin R. B., Schneeberger E. E., et al. Widespread and selective induction of major histocompatibility complex-determined antigens in vivo by gamma interferon. J Exp Med. 1985; 162: 1645–64
   PubMed Web of Science ®Google Scholar
• Blancho G., Moreau J. F., Chabannes D., et al. HILDA/LIF, G.CSF, IL-1 beta, IL-6, and TNF alpha production during acute rejection of human kidney allografts. Transplantation 1993; 56: 597–602
   PubMed Web of Science ®Google Scholar
• Cunningham D. A., Dunn M. J., Yacoub M. H., et al. Local production of cytokines in the human cardiac allograft. A sequential study. Transplantation 1994; 57: 1333–7
   PubMed Web of Science ®Google Scholar
• Martinez O. M., Krams SM, Sterneck M., et al. Intragraft cytokine profile during human liver allograft rejection. Transplantation 1992; 53: 449–56
   PubMed Web of Science ®Google Scholar
• Pattison J., Nelson P. J., Huie P., et al. RANTES chemokine expression in cell-mediated transplant rejection of the kidney. Lancet. 1994; 343: 209–11
   PubMed Web of Science ®Google Scholar
• Vandenbroecke C., Caillat-Zucman S., Legendre C., et al. Differential in situ expression of cytokines in renal allograft rejection. Transplantation 1991; 51: 602–9
   PubMed Web of Science ®Google Scholar
• Whitehead B. F., Stoehr C., Wu C. J., et al. Cytokine gene expression in human lung transplant recipients. Transplantation 1993; 56: 956–61
   PubMed Web of Science ®Google Scholar
• Yard B. A., Kooymans-Couthino M., Paape M. E., et al. Analysis of cytokine production by graft-infiltrating cells isolated from rejecting renal allografts. Transplantation 1994; 57: 153–5
   PubMed Web of Science ®Google Scholar
• Zhao X. M., Frist W. H., Yeoh T. K., et al. Expression of cytokine genes in human cardiac allografts: correlation of IL-6 and transforming growth factor-beta (TGF-beta) with histological rejection. Clin Exp Immunol 1993; 93: 448–51
   PubMed Web of Science ®Google Scholar
• Williams G. M., Hume D. M., Hudson R., Jr, et al. “Hyperacute” renal-homograft rejection in man. N Engl J Med. 1968; 279: 611–8
   PubMed Web of Science ®Google Scholar
• Kissmeyer-Nielsen F., Olsen S., Peterson V. P., et al. Hyperacute rejection of kidney allografts associated with pre-existing humoral antibodies against donor cells. Lancet. 1996; 2: 662–5
   Google Scholar
• Halloran P. F., Schlaut J., Solez K., et al. The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 1992; 53: 550–5
   PubMed Web of Science ®Google Scholar
• Paul L. C., Fellstrom B. Chronic vascular rejection of the heart and the kidney – have rational treatment options emerged%. Transplantation 1992; 53: 1169–79
   PubMed Web of Science ®Google Scholar
• Tilney N. L., Whitley W. D., Diamond J. R., et al. Chronic rejection – an undefined conundrum. Transplantation 1991; 52: 389–98
   PubMed Web of Science ®Google Scholar
• Kerman R. H., Kimball P. M., Lindholm A., et al. Influence of HLA matching on rejections and short- and long-term primary cadaveric allograft survival. Transplantation 1993; 56: 1242–7
   PubMed Web of Science ®Google Scholar
• Takemoto S., Terasaki P. I., Cecka J. M., et al. Survival of nationally shared. HLA-matched kidney transplants from cadaveric donors. The UNOS Scientific Renal Transplant Registry. N Engl J Med. 1992; 327: 834–9
   PubMed Web of Science ®Google Scholar
• Opelz G., Mytilineos J., Scherer S., et al. Analysis of HLA-DR matching in DNA-typed cadaver kidney transplants. Transplantation 1993; 55: 782–5
   PubMed Web of Science ®Google Scholar
• Bierer B. E., Hollander G., Fruman D., et al. Cyclosporin A and FK 506: molecular mechanisms of immunosuppression and probes for transplantation biology. Curr Opin Immunol. 1993; 5: 763–73
   PubMed Web of Science ®Google Scholar
• Kunz J., Hall M. N. Cyclosporin A., FK506 and rapamycin: more than just immunosuppression. Trends Biochem Sci. 1993; 18: 334–8
   PubMed Web of Science ®Google Scholar
• Liu J. FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. Immunol Today 1993; 14: 290–5
   PubMedGoogle Scholar
• Zenke G., Baumann G., Wenger R., et al. Molecular mechanisms of immunosuppression by cyclosporins. Ann NY Acad Sci. 1993; 685: 330–5
   PubMed Web of Science ®Google Scholar
• Morris P. J. Cyclosporine, FK-506 and other drugs in organ transplantation. Curr Opin Immunol 1991; 3: 748–51
   PubMed Web of Science ®Google Scholar
• Soldin S. J., Murthy J. N., Donnelly J. G., et al. Immunophilin receptors for immunosuppressive drugs. Ther Drug Monit 1993; 15: 468–71
   PubMed Web of Science ®Google Scholar
• Wiederrecht G., Lam E., Hung S., et al. The mechanism of action of FK-506 and cyclosporin A. Ann NY Acad Sci. 1993; 696: 9–19
   PubMed Web of Science ®Google Scholar
• Quesniaux V. F. Immunosuppressants: tools to investigate the physiological role of cytokines. Bioessays 1993; 15: 731–9
   PubMed Web of Science ®Google Scholar
• Makowka L., Sher LS, Cramer D. V. The development of Brequinar as an immunosuppressive drug for transplantation. Immunol Rev. 1993; 136: 51–70
   PubMed Web of Science ®Google Scholar
• Morris R. E. New small molecule immunosuppressants for transplantation: review of essential concepts. J Heart Lung Transplant. 1993; 12: S275–86
   Web of Science ®Google Scholar
• Ortho, Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med. 1985; 313: 337–42
   PubMed Web of Science ®Google Scholar
• Norman D. J., Shield C., Barry J., et al. Early use of OKT3 monoclonal antibody in renal transplantation to prevent rejection. Am J Kidney Dis. 1988; 11: 107–10
   PubMed Web of Science ®Google Scholar
• Goldstein G., Fuccello A. J., Norman D. J., et al. OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3. Transplantation 1986; 42: 507–11
   PubMed Web of Science ®Google Scholar
• Soulillou J. P., Cantarovich D., Le Mauff B., et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts [see comments]. N Engl J Med. 1990; 322: 1175–82
   PubMed Web of Science ®Google Scholar
• Le Mauff B., Hourmant M., Rougier J. P. et al. Effect of anti-LFAl (CDlla) monoclonal antibodies in acute rejection in human kidney transplantation. Transplantation 1991; 52: 291–6
   PubMed Web of Science ®Google Scholar
• Waid T. H., Lucas B. A., Thompson J. S., et al. Treatment of acute cellular rejection with Tl 0B9.1A-31 or OKT3 in renal allograft recipients. Transplantation 1992; 53: 80–6
   PubMed Web of Science ®Google Scholar
• Knight R. J., Kurrle R., McClain J., et al. Clinical evaluation of induction immunosuppression with a murine IgG2b monoclonal antibody (BMA 031) directed toward the human alpha/beta-T cell receptor. Transplantation 1994; 57: 1581–8
   PubMed Web of Science ®Google Scholar
• Haug C. E., Colvin R. B., Delmonico F. L., et al. A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients. Transplantation 1993; 55: 766–72
   PubMed Web of Science ®Google Scholar
• Lin H., Boiling S. F., Linsley P. S., et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med. 1993; 178: 1801–6
   PubMed Web of Science ®Google Scholar
• Starzl T. E., Demetris A. J., Trucco M., et al. Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med. 1993; 328: 745–9
   PubMed Web of Science ®Google Scholar
• Caillat-Zucman S., Legendre C., Suberbielle C., et al. Microchimerism frequency two to thirty years after cadaveric kidney transplantation. Hum Immunol 1994; 41: 91–5
   PubMed Web of Science ®Google Scholar
• Parham P., Lomen C. E., Lawlor D. A., et al. Nature of polymorphism in HLA-A, -B, and -C molecules. Proc Natl Acad Sci USA 1988; 85: 4005–9
   PubMed Web of Science ®Google Scholar
• Schwartz B. D., Luehrman LK, Rodey G. E. Public antigenic determinant on a family of HLA-B molecules. J Clin Invest 1979; 64: 938–47
   PubMed Web of Science ®Google Scholar
• Rodey G. E., Fuller T. C. Public epitopes and the antigenic structure of the HLA molecules. Crit Rev Immunol 1987; 7: 229–67
   PubMed Web of Science ®Google Scholar
• Konoeda Y., Terasaki P. I., Wakisaka A., et al. Public determinants of HLA indicated by pregnancy antibodies. Transplantation 1986; 41: 253–9
   PubMed Web of Science ®Google Scholar
• Duquesnoy R. J., White L. T., Fierst J. W., et al. Multiscreen serum analysis of highly sensitized renal dialysis patients for antibodies toward public and private class I HLA determinants. Implications for computer-predicted acceptable and unacceptable donor mismatches in kidney transplantation. Transplantation 1990; 50: 427–37
   PubMed Web of Science ®Google Scholar
• Fuller T. C. Monitoring HLA alloimmunization. Analysis of HLA alloantibodies in the serum of prospective transplant recipients. Clin Lab Med 1991; 11: 551–70
   PubMed Web of Science ®Google Scholar
• Fuller T. C. Antigenic specificity of antibody reactive in the antiglobulin-augmented lymphocytotoxicity test. Transplantation 1982; 34: 24–9
   PubMed Web of Science ®Google Scholar
• Rodey G. E., Neylan J. F., Whelchel J. D., et al. Epitope specificity of antibodies to private versus public specificities in potential transplant recipients. Hum Immunol 1994; 39: 272–80
   PubMed Web of Science ®Google Scholar
• Cross D. E., Greiner R, Whittier F. C. Importance of the autocontrol crossmatch in human renal transplantation. Transplantation 1976; 21: 307–11
   PubMed Web of Science ®Google Scholar
• Ettenger R. B., Jordan SC, Fine R. N. Cadaver renal transplant outcome in recipients with autolymphocytotoxic antibodies. Transplantation 1983; 35: 429–31
   PubMed Web of Science ®Google Scholar
• Ting A., Morris P. J. Successful transplantation with a positive T and B cell crossmatch due to autoreactive antibodies. Tissue Antigens 1983; 21: 219–26
   PubMedGoogle Scholar
• Chapman J. R., Taylor C. J., Ting A., et al. Immunoglobulin class and specificity of antibodies causing positive T cell crossmatches. Relationship to renal transplant outcome. Transplantation 1986; 42: 608–13
   PubMed Web of Science ®Google Scholar
• Vaidya S., Ruth J. Contributions and clinical significance of IgM and autoantibodies in highly sensitized renal allograft recipients. Transplantation 1989; 47: 956–8
   PubMed Web of Science ®Google Scholar
• Tellis V. A., Matas A. J., Senitzer D., et al. Successful transplantation after conversion of a positive crossmatch to negative by dissociation of IgM antibody. Transplantation 1989; 47: 127–9
   PubMed Web of Science ®Google Scholar
• Amos D. B., Bashir H., Boyle W., et al. A simple microcytotoxicity test. Transplantation 1969; 7: 220–3
   PubMed Web of Science ®Google Scholar
• Johnson A. H., Rossen RD, Butler W. T. Detection of alloantibodies using a sensitive antiglobulin microcytotoxicity test: identification of low levels of pre-formed antibodies in accelerated allograft rejection. Tissue Antigens 1972; 2: 215–26
   PubMedGoogle Scholar
• Barger B. O., Shroyer S. L., Hudson M. H., et al. Successful renal allografts in recipients with a positive standard, DTE negative cross-match. Transplant Proc 1989; 21: 746–9
   PubMed Web of Science ®Google Scholar
• Alarif L., Snyder T, Light J. A. Transplantation of highly sensitized patients based on crossmatches using DTT-treated sera. Transplant Proc 1989; 21: 742–4
   PubMed Web of Science ®Google Scholar
• Brasile L., Zerke T., Rabin B., et al. Identification of the antibody to vascular endothelial cells in patients undergoing cardiac transplantation. Transplantation 1985; 40: 672–5
   PubMed Web of Science ®Google Scholar
• Cerilli J., Brasile L., Gralonzis T., et al. The vascular endothelial cell antigen system. Transplantation 1985; 32: 286–9
   Google Scholar
• Moraes J. R., Moraes M. E., Luo Y. M., et al. Alloantibodies against donor epidermis and early kidney transplant rejection. Transplantation 1991; 51: 370–3
   PubMed Web of Science ®Google Scholar
• Paul L. C., Baldwin WM, III, van Es L. A. Vascular endothelial alloantigens in renal transplantation. Transplantation 1985; 40: 117–23
   PubMed Web of Science ®Google Scholar
• O'Connell P. J., McKenzie A., Tait B. D., et al. The incidence of antimonocyte alloantibodies. Evidence that prospective crossmatching is unnecessary. Transplantation 1990; 50: 261–4
   PubMed Web of Science ®Google Scholar
• Leichter H. E., Ettenger R. B., Robertson L., et al. Significance of the monocyte crossmatch in living-related transplantation. Child Nephrol Urol 1990; 10: 186–8
   PubMedGoogle Scholar
• Cerilli J., Bay WBrasile L. The significance of the monocyte crossmatch in recipients of living-related HLA identical kidney grafts. Hum Immunol 1983; 7: 45–50
   PubMed Web of Science ®Google Scholar
• Yard B., Spruyt-Gerritse M., Claas F., et al. The clinical significance of allospecific antibodies against endothelial cells detected with an antibody-dependent cellular cytotoxicity assay for vascular rejection and graft loss after renal transplantation. Transplantation 1993; 55: 1287–93
   PubMed Web of Science ®Google Scholar
• Simpson E. Minor histocompatibility antigens. Immunol Lett 1991; 29: 9–14
   PubMed Web of Science ®Google Scholar
• Joyce S., Mathew J. M., Flye M. W., et al. A polymorphic human kidney-specific non-MHC alloantigen. Transplantation 1992; 53: 1119–27
   PubMed Web of Science ®Google Scholar
• Mohanakumar T., Waidrep J. C., Phibbs M., et al. Serological characterization of antibodies eluted from chronically rejected human renal allografts. Transplantation 1981; 32: 61–6
   PubMed Web of Science ®Google Scholar
• Joyce S., Flye M. W., Mohanakumar T. Characterization of kidney cell-specific, non-major histocompatibility complex alloantigen using antibodies eluted from rejected human renal allografts. Transplantation 1988; 46: 362–9
   PubMed Web of Science ®Google Scholar
• Dunn M. J., Rose M. L., Latif N., et al. Demonstration by western blotting of antiheart antibodies before and after cardiac transplantation. Transplantation 1991; 51: 806–12
   PubMed Web of Science ®Google Scholar
• Terasaki P. I., McClelland J. D. Microdroplet assay of human serum cytotoxins. Nature 1964; 204: 998–1000
   PubMed Web of Science ®Google Scholar
• Bidwell J. Advances in DNA-based HLA-typing methods. Immunol Today 1994; 15: 303–7
   PubMedGoogle Scholar
• Olerup O., Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225–35
   PubMed Web of Science ®Google Scholar
• Salazar M., Deulofeut R., Yunis J. J., et al. A fast PCR-SSP method for HLA-DQ generic typing. Tissue Antigens 1993; 41: 102–6
   PubMedGoogle Scholar
• Kao K. J., Scornik JC, Small S. J. Enzyme-linked immunoassay for anti-HLA antibodies – an alternative to panel studies by lymphocytotoxicity. Transplantation 1993; 55: 192–6
   PubMed Web of Science ®Google Scholar
• Scomik J. C. Crossmatch for renal transplantation. A report from the Clinical Affairs Committee. A SHI Q 1991; 15: 24–7
   Google Scholar
• Ting A., Hasegawa T., Ferrone S., et al. Presensitization detected by sensitive crossmatch tests. Transplant Proc 1973; 5: 813–7
   PubMed Web of Science ®Google Scholar
• Fuller T. C., Cosimi AB, Russell P. S. Use of an antiglobulin-ATG reagent for detection of low levels of alloantibody-improvement of allograft survival in presensitized recipients. Transplant Proc 1978; 10: 463–6
   PubMed Web of Science ®Google Scholar
• Marrari M., Duquesnoy R. J. Progress report on the ASHI/CAP Proficiency Survey Program in Histocompatibility Testing. I. HLA-A,B,C typing, antibody screening, and lymphocytotoxicity crossmatching. American Society for Histocompatibility and Immunogenetics. College of American Pathologists. Hum Immunol 1994; 39: 87–95
   PubMed Web of Science ®Google Scholar
• Kerman R. H., Van Buren C. T., Lewis R. M., et al. Improved graft survival for flow cytometry and antihuman globulin crossmatch-negative retransplant recipients. Transplantation 1990; 49: 52–6
   PubMed Web of Science ®Google Scholar
• Stratta R. J., Mason B., Lorentzen D. F., et al. Cadaveric renal transplantation with quadruple immunosuppression in patients with a positive antiglobulin crossmatch. Transplantation 1989; 47: 282–6
   PubMed Web of Science ®Google Scholar
• Dafoe D. C., Bromberg J. S., Grossman R. A., et al. Renal transplantation despite a positive antiglobulin crossmatch with and without prophylactic OKT3. Transplantation 1991; 51: 762–8
   PubMed Web of Science ®Google Scholar
• Garovoy M. R., Rheinschmidt M. A., Bigos M., et al. Flow cytometry analysis: a high technology crossmatch technique facilitating transplantation. Transplant Proc 1983; 15: 1939–44
   Web of Science ®Google Scholar
• Chapman J., Deierhoi M., Carter N., et al. Analysis of flow cytometry and cytotoxicity crossmatches in renal transplantation. Transplant Proc 1985; 17: 2480–1
   Web of Science ®Google Scholar
• Thistlethwaite J. R., Buckingham M. R., Gaber A. O., et al. T cell immunofluorescence flow cytometry crossmatch results in cadaver donor renal transplantation. Transplant Proc 1987; 19: 722–1
   PubMed Web of Science ®Google Scholar
• Karuppan S. S., Lindholm A, Moller E. Fewer acute rejection episodes and improved outcome in kidney-transplanted patients with selection criteria based on crossmatching. Transplantation 1992; 53: 666–73
   PubMed Web of Science ®Google Scholar
• Talbot D., Cavanagh G., Coates E., et al. Improved graft outcome and reduced complications due to flow cytometry crossmatching and DR matching in renal transplantation. Transplantation 1992; 53: 925–8
   PubMed Web of Science ®Google Scholar
• Kuijpers R. W., Dooren M. C., von dem Borne A. E., et al. Detection of human monocyte-reactive alloantibodies by flow cytometry after selective downmodulation of the Fc receptor I. Blood 1991; 78: 2150–6
   PubMed Web of Science ®Google Scholar
• Wang G. X., Terashita GY, Terasaki P. I. Platelet crossmatching for kidney transplants by flow cytometry. Transplantation 1989; 48: 959–61
   PubMed Web of Science ®Google Scholar
• Rao K., Adrisevic J. Prolonged cold ischemia time exerts an independent adverse effect on graft survival recipients of cadaver renal transplants. Transplant Proc 1988; 20: 942–3
   PubMed Web of Science ®Google Scholar
• Butkus D. E., Meydrech EF, Raju S. S. Racial differences in the survival of cadaveric renal allografts. N Engl J Med 1992; 327: 840–5
   PubMed Web of Science ®Google Scholar
• Gjertson D. W., Terasaki P. I. The large center variation in half-lives of kidney transplants. Transplantation 1992; 53: 357–62
   PubMed Web of Science ®Google Scholar
• Kahan B. D., Mickey R., Flechner S. M., et al. Multivariate analysis of risk factors impacting on immediate and eventual cadaver allograft survival in cyclosporine-treated recipients. Transplantation 1987; 43: 65–70
   PubMed Web of Science ®Google Scholar
• Ackerman J. R., Mendez R., Shires D. L., et al. Hyperacute and acute kidney graft rejection due to antibodies against B cells. Transplantation 1992; 54: 61–4
   PubMed Web of Science ®Google Scholar
• Ayoub G., Park M. S., Terasaki P. I., et al. B cell antibodies and crossmatching. Transplantation 1980; 29: 227–9
   PubMed Web of Science ®Google Scholar
• Balakrishnan K., Munda R., First M. R., et al. Outcome of donor specific transfusion renal transplants across B cell positive crossmatches. Transplant Proc 1989; 21: 1836
   PubMed Web of Science ®Google Scholar
• Ettenger R. B., Uittenbogaart C. H., Pennisi A. J., et al. Long-term cadaver allograft survival in the recipient with a positive B lymphocyte crossmatch. Transplantation 1979; 27: 315–8
   PubMed Web of Science ®Google Scholar
• Hourmant M., Vergracht A., Bignon J. D., et al. Effect of a positive crossmatch against donor B-lymphocytes in kidney transplantation: a prospective one-center study. Transplant Proc 1990; 22: 1881–2
   PubMed Web of Science ®Google Scholar
• Jendrisak M., Phelan D., Marsh J., et al. Significance of B-cell crossmatch on outcome in renal transplantation. Transplant Proc 1991; 23: 434–6
   PubMed Web of Science ®Google Scholar
• Karuppan S. S., Lindholm A, Moller E. Characterization and significance of donor-reactive B cell antibodies in current sera of kidney transplant patients. Transplantation 1990; 49: 510–5
   PubMed Web of Science ®Google Scholar
• Mohanakumar T., Rhodes C., Mendez-Picon G., et al. Renal allograft rejection associated with presensitization to HLA-DR antigens. Transplantation 1981; 31: 93–5
   PubMed Web of Science ®Google Scholar
• Noreen H. J., van der Hagen E., Bach F. H., et al. Renal allograft survival in CSA-treated patients with positive donor-specific B cell crossmatches. Transplant Proc 1989; 21: 691–2
   PubMedGoogle Scholar
• Scornik J. C., LeFor W. M., Cicciarelli J. C., et al. Hyperacute and acute kidney graft rejection due to antibodies against B cells. Transplantation 1992; 54: 61–4
   PubMed Web of Science ®Google Scholar
• Pellegrino M. A., Belvedere M., Pellegrino A. G., et al. B peripheral lymphocytes express more HLA antigens than T peripheral lymphocytes. Transplantation 1978; 25: 93–5
   PubMed Web of Science ®Google Scholar
• Ting A. Positive crossmatches – when is it safe to transplant%. Transplant Int 1989; 2: 2–7
   PubMed Web of Science ®Google Scholar
• Scomik J. C., Branson M. E., Schaub B., et al. The crossmatch in renal transplantation. Evaluation of flow cytometry as a replacement for standard cytotoxicity. Transplantation 1994; 57: 621–5
   PubMed Web of Science ®Google Scholar
• Bray R. A., Lebeck LK, Gebel H. M. The flow cytometric crossmatch. Dual color analysis of T cell and B cell reactivities. Transplantation 1989; 834: 834–40
   Google Scholar
• Mahoney R. J., Ault K. A., Given S. R., et al. The flow cytometric crossmatch and early transplant loss. Transplantation 1990; 49: 527–35
   PubMed Web of Science ®Google Scholar
• Gaston R. S., Shroyer TW, Hudson S. L., et al. Renal retransplantation: the role of race, quadruple immunosuppression, and the flow cytometry cross-match. Transplantation 1994; 57: 47–54
   PubMed Web of Science ®Google Scholar
• Bou-Habib J. C., Krams S., Colombe B. W., et al. Impaired kidney graft survival in flow cytometric crossmatched positive donor-specific transfusion recipients. Transplant Proc 1991; 23: 403–4
   PubMed Web of Science ®Google Scholar
• Sridhar N. R., Munda R., Balakrishnan K., et al. Evaluation of flow cytometric crossmatching in renal allograft recipients. Nephron 1992; 62: 262–6
   PubMed Web of Science ®Google Scholar
• Ogura K., Terasaki P. I., Johnson C., et al. The significance of a positive flow cytometry crossmatch test in primary kidney transplantation. Transplantation 1993; 56: 294–8
   PubMed Web of Science ®Google Scholar
• Murphey C, McFarlin L., Morrisey J., et al. Renal allograft survival; An assessment on the age of current serum for final crossmatch. Clin Transplant. 1990; 4: 254–6
   Web of Science ®Google Scholar
• Cardella C. J., Falk J. A., Nicholson M. J., et al. Successful renal transplantation in patients with T-cell reactivity to donor. Lancet 1982; II: 1240–3
   Google Scholar
• Cardella C. J. The use of the kidney with an historical positive, and current negative crossmatch. Pediatr Nephrol. 1991; 5: 126–9
   PubMed Web of Science ®Google Scholar
• Guerin C., Pomier G., Laverne S., et al. Renal transplantation with a current T negative but historical T and/or B positive cross-match. Nephrol Dial Transplant. 1991; 6: 280–5
   PubMed Web of Science ®Google Scholar
• Kerman R. H., Flechner S. M., Van Buren C. T., et al. Successful transplantation of cyclosporine-treated allograft recipients with serologically positive historical, but negative preoperative, donor crossmatches. Transplantation 1985; 40: 615–9
   PubMed Web of Science ®Google Scholar
• Opelz G. Relevance of “remote positive” crossmatches and positive B-cell crossmatches in renal transplantation. Transplant Proc 1990; 22: 1878–80
   PubMed Web of Science ®Google Scholar
• Taylor C. J., Chapman J. R., Ting A., et al. Characterization of ly mphocytotoxic antibodies causing a positive crossmatch in renal transplantation. Relationship to primary and regraft outcome. Transplantation 1989; 48: 953–8
   PubMed Web of Science ®Google Scholar
• Turka L. A., Goguen J. E., Gagne J. E., et al. Presensitization and the renal allograft recipient. Transplantation 1989; 47: 234–40
   PubMed Web of Science ®Google Scholar
• Norman D. J., Barry JM, Wetzsteon P. J. Successful cadaver kidney transplantation in patients highly sensitized by blood transfusions. Unimportance of the most reactive serum in the pretransplant crossmatch. Transplantation 1985; 39: 253–5
   PubMed Web of Science ®Google Scholar
• Hoorten G. M., Coopmans M, Allebes W. A. Specificity and Ig class of preformed alloantibodies causing a positive crossmatch in renal transplantation. The implications for graft survival. Transplantation 1993; 56: 298–304
   PubMed Web of Science ®Google Scholar
• Kerman R. H., Kimball P. M., Van Buren C. T., et al. Influence of race on crossmatch outcome and recipient eligibility for transplantation. Transplantation 1992; 53: 64–7
   PubMed Web of Science ®Google Scholar
• Koyama H. Cecka JM Terasaki PL Kidney transplants in black recipients. HLA matching and other factors affecting long-term graft survival. Transplantation 1994; 57: 1064–8
   PubMed Web of Science ®Google Scholar
• Cecka J. M., Terasaki P. I. Repeating HLA antigen mismatches in renal retransplants – a second class mistake%. Transplantation 1994; 57: 515–9
   PubMed Web of Science ®Google Scholar
• Ratkovec R. M., Hammond E. H., O'Connell J. B., et al. Outcome of cardiac transplant recipients with a positive donor-specific crossmatch – preliminary results with plasmapheresis. Transplantation 1992; 54: 651–5
   PubMed Web of Science ®Google Scholar
• Gannedahl G., Ohiman S., Persson U., et al. Rejection associated with early appearance of donor-reactive antibodies after kidney transplantation treated with plasmapheresis and administration of 15-deoxyspergualin. A report of two cases. Transplant Int. 1992; 5: 189–92
   PubMed Web of Science ®Google Scholar
• Malafa M., Mancini M. C., Myles J. L., et al. Successful treatment of acute humoral rejection in a heart transplant patient. J Heart Lung Transplant 1992; 11: 486–91
   PubMed Web of Science ®Google Scholar
• Haberal M., Bulut O., Sen S., et al. Treatment of steroid-resistant renal allograft rejection with OKT-3 and plasmapheresis. Ren Fail 1991; 13: 43–7
   PubMed Web of Science ®Google Scholar
• Hakim R. M., Milford E., Himmelfarb J., et al. Extracorporeal removal of anti-HLA antibodies in transplant candidates. Am J Kidney Dis 1990; 16: 423–31
   PubMed Web of Science ®Google Scholar
• Evrard H. M., Miller C., Schwartz M., et al. Resistant hepatic allograft rejection successfully treated with cyclophosphamide and plasmapheresis. Transplantation 1990; 50: 702–4
   PubMed Web of Science ®Google Scholar
• Ross C. N., Gaskin G., Gregor-Macgregor S., et al. Renal transplantation following immunoadsorption in highly sensitized recipients. Transplantation 1993; 55: 785–9
   PubMed Web of Science ®Google Scholar
• Tyan D. B., Li V. A., Czer L., et al. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994; 57: 553–62
   PubMed Web of Science ®Google Scholar
• Freese D. K., Snover D. C., Sharp H. L., et al. Chronic rejection after liver transplantation: a study of clinical, histopathological and immunological features. Hepatology 1991; 13: 882–91
   PubMed Web of Science ®Google Scholar
• Steinhoff G., Wonigeit K, Pichlmayr R. Analysis of sequential changes in major histocompatibility complex expression in human liver grafts after transplantation. Transplantation 1988; 45: 394–401
   PubMed Web of Science ®Google Scholar
• Daar A. S., Fuggle S. V., Fabre J. W., et al. The detailed distribution of HLA-A, B, C antigens in normal human organs. Transplantation 1984; 38: 287–92
   PubMed Web of Science ®Google Scholar
• Davies H. S., Pollard SG, Calne R. Y. Soluble HLA antigens in the circulation of liver graft recipients. Transplantation 1989; 47: 524–7
   PubMed Web of Science ®Google Scholar
• Wardle E. N. Kupffer cells and their function. Liver. 1987; 7: 63–75
   PubMedGoogle Scholar
• Takaya S., Bronsther O., Iwaki Y., et al. The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation 1992; 53: 400–6
   PubMed Web of Science ®Google Scholar
• Katz S. M., Kimball P. M., Ozaki C., et al. Positive pretransplant crossmatches predict early graft loss in liver allograft recipients. Transplantation 1994; 57: 616–20
   PubMed Web of Science ®Google Scholar
• Ogura K., Terasaki P. I., Koyama H., et al. High one-month liver graft failure rates in flow cytometry crossmatch-positive recipients. Clin Transplant. 1994; 8: 111–5
   PubMed Web of Science ®Google Scholar
• Ensley R. D., Hunt S., Taylor D. O., et al. Predictors of survival after repeat heart transplantation. The Registry of the International Society for Heart and Lung Transplantation, and Contributing Investigators. J Heart Lung Transplant 1992; 11: S142–58
   PubMed Web of Science ®Google Scholar
• Lavee J., Kormos R. L., Duquesnoy R. J., et al. Influence of panel-reactive antibody and lymphocytotoxic crossmatch on survival after heart transplantation. J Heart Lung Transplant 1991; 10: 921–9, discussion 929–30
   PubMed Web of Science ®Google Scholar
• Smith J. D., Danskine A. J., Rose M. L., et al. Specificity of lymphocytotoxic antibodies formed after cardiac transplantation and correlation with rejection episodes. Transplantation 1992; 53: 1358–62
   PubMed Web of Science ®Google Scholar
• Morris P. J. HLA matching and cardiac transplantation. N Engl J Med 1994; 330: 857–8
   PubMed Web of Science ®Google Scholar
• Joysey V. C. Tissue typing, heart and heart-lung transplantation. Br J Biomed Sci 1993; 50: 272–6
   PubMed Web of Science ®Google Scholar
• Opelz G., Wujciak T. The influence of HLA compatibility on graft survival after heart transplantation. The Collaborative Transplant Study. N Engl J Med 1994; 330: 816–9
   PubMed Web of Science ®Google Scholar
• Frist W. H., Oyer P. E., Baldwin J. C., et al. HLA compatibility and cardiac transplant recipient survival. Ann Thorac Surg 1987; 44: 242–6
   PubMed Web of Science ®Google Scholar
• Pfeffer P. F., Foerster A., Froysaker T., et al. HLA-DR mismatch and histologically evaluated rejection episodes in cardiac transplants can be correlated. Transplant Proc 1988; 20: 367–8
   PubMed Web of Science ®Google Scholar
• Zerbe T. R., Arena V. C., Kormos R. L., et al. Histocompatibility and other risk factors for histological rejection of human cardiac allografts during the first three months following transplantation. Transplantation 1991; 52: 485–90
   PubMed Web of Science ®Google Scholar
• Cocanougher B., Ballantyne C. M., Pollack M. S., et al. Degree of HLA mismatch as a predictor of death from allograft arteriopathy after heart transplant. Transplant Proc 1993; 25: 233–6
   PubMed Web of Science ®Google Scholar